Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Apr 15;117(8):1736-44.
doi: 10.1002/cncr.25744. Epub 2010 Nov 8.

Addition of pamidronate to chemotherapy for the treatment of osteosarcoma

Paul A Meyers  1 , John H Healey, Alexander J Chou, Leonard H Wexler, Pamela R Merola, Carol D Morris, Michael P Laquaglia, Michael G Kellick, Sara J Abramson, Richard Gorlick
Affiliations
Clinical Trial

Addition of pamidronate to chemotherapy for the treatment of osteosarcoma

Paul A Meyers et al. Cancer. .

Abstract

Background: This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma.

Methods: The authors treated 40 patients with osteosarcoma with cisplatin, doxorubicin, and methotrexate with the addition of pamidronate 2 mg/kg/dose (max dose 90 mg) monthly for 12 doses. Survival, event-free survival (EFS), and durability of orthopedic reconstruction were evaluated.

Results: For patients with localized disease, event-free survival (EFS) at 5 years was 72% and overall survival 93%. For patients with metastatic disease, EFS at 5 years was 45% and overall survival 64%. Toxicity was similar to patients treated with chemotherapy alone. Thirteen of 14 uncemented implants demonstrated successful osteointegration. Among allograft reconstructions, there were 2 graft failures, 4 delayed unions, and 6 successful grafts. Overall, 5 of 33 reconstructions failed. There were no stress fractures or growth disturbances.

Conclusions: Pamidronate can be safely incorporated with chemotherapy for the treatment of osteosarcoma. It does not impair the efficacy of chemotherapy. Pamidronate may improve the durability of limb reconstruction.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Event free survival for patients who presented with localized or metastatic osteosarcoma at initial presentation.
Figure 2
Figure 2
Overall survival for patients who presented with localized or metastatic osteosarcoma at initial presentation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Meyers PA, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10(1):5–15. - PubMed
    1. Link MP, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600–6. - PubMed
    1. Baum ES, et al. Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children’s Cancer Study Group Report. Cancer Treat Rep. 1979;63(9–10):1621–7. - PubMed
    1. Cortes EP, Holland JF, Wang JJ, Sinks LF. Doxorubicin in disseminated osteosarcoma. JAMA. 1972;3144(25):1132–1138. - PubMed
    1. Jaffe N, et al. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer. 1973;31(6):1367–73. - PubMed

Publication types